

Stephan A Grupp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1451813/publications.pdf>

Version: 2024-02-01

229
papers

33,408
citations

20817

60
h-index

4117

175
g-index

230
all docs

230
docs citations

230
times ranked

22566
citing authors

#	ARTICLE	IF	CITATIONS
1	Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. <i>Journal of Clinical Oncology</i> , 2022, 40, 932-944.	1.6	93
2	Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 66-81.	5.0	70
3	Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR-T-cell therapy. <i>Blood</i> , 2022, 139, 2173-2185.	1.4	39
4	Unrelated donor $\hat{\pm}$ T cell $\hat{\pm}$ and B cell $\hat{\pm}$ depleted HSCT for the treatment of pediatric acute leukemia. <i>Blood Advances</i> , 2022, 6, 1175-1185.	5.2	9
5	Potential Role of IFN $\hat{\pm}$ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy. <i>Blood Cancer Discovery</i> , 2022, 3, 90-94.	5.0	23
6	Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1508-1515.	7.2	21
7	Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. <i>Blood</i> , 2022, 140, 619-629.	1.4	45
8	Impact of diagnostic and end-of-induction Curie scores in tandem autologous hematopoietic cell transplant for patients with high-risk neuroblastoma: A report from the Children $\hat{\pm}$ s Oncology Group.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10027-10027.	1.6	0
9	Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. <i>Science Advances</i> , 2022, 8, .	10.3	63
10	Impact of socioeconomic status on survival after CD19 CART therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7013-7013.	1.6	0
11	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell $\hat{\pm}$ Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. <i>Clinical Cancer Research</i> , 2022, 28, 3804-3813.	7.0	17
12	Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies. <i>Clinical Cancer Research</i> , 2022, 28, 3940-3949.	7.0	4
13	CAR-T cells: Early successes in blood cancer and challenges in solid tumors. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1129-1147.	12.0	47
14	Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 88.e1-88.e6.	1.2	4
15	Immune Reconstitution Following TCR $\hat{\pm}$ /CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 169.e1-169.e9.	1.2	9
16	Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. <i>Blood Advances</i> , 2021, 5, 593-601.	5.2	28
17	Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells $\hat{\pm}$ off the shelf $\hat{\pm}$? <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 195-196.	27.6	21
18	Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 920-930.	1.6	110

#	ARTICLE	IF	CITATIONS
19	Improving and Maintaining Responses in Pediatric Bâ€‘Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptorâ€‘T Cell Therapy. Cancer Journal (Sudbury, Mass), 2021, 27, 151-158.	2.0	0
20	Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy. Cancer Discovery, 2021, 11, 2186-2199.	9.4	85
21	Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nature Medicine, 2021, 27, 842-850.	30.7	88
22	Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse. Blood Advances, 2021, 5, 2128-2136.	5.2	26
23	Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. , 2021, 9, e002328.		31
24	A safety and feasibility trial of ¹³¹ Iâ€‘MIBG in newly diagnosed highâ€‘risk neuroblastoma: A Children's Oncology Group study. Pediatric Blood and Cancer, 2021, 68, e29117.	1.5	17
25	Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 988.e1-988.e7.	1.2	10
26	Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Advances, 2021, 5, 4980-4991.	5.2	12
27	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24
28	Distinct Bioenergetic Features of Human Invariant Natural Killer T Cells Enable Retained Functions in Nutrient-Deprived States. Frontiers in Immunology, 2021, 12, 700374.	4.8	3
29	Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers. Bone Marrow Transplantation, 2021, 56, 2869-2870.	2.4	3
30	Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2021, 39, 3044-3055.	1.6	94
31	CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematology, 2021, 8, e711-e722.	4.6	57
32	Beyond the storm â€” subacute toxicities and late effects in children receiving CAR T cells. Nature Reviews Clinical Oncology, 2021, 18, 363-378.	27.6	37
33	Ex Vivo T-Cell Receptor α +/CD19 +depletion of Peripheral Stem Cell Grafts for Pediatric Patients with Bone Marrow Failure (BMF) Undergoing Unrelated Donor Transplantation. Blood, 2021, 138, 171-171.	1.4	0
34	Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors. Blood, 2021, 138, 1727-1727.	1.4	7
35	Prognostic Value of Elafin in Acute Graft-Versus-Host Disease. Blood, 2021, 138, 3900-3900.	1.4	0
36	Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Blood, 2021, 138, 474-474.	1.4	11

#	ARTICLE	IF	CITATIONS
37	Ikaros Mediates Antigen Escape Following CD19 CAR T Cell Therapy in r/r B-ALL. <i>Blood</i> , 2021, 138, 613-613.	1.4	4
38	Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. <i>Blood</i> , 2021, 138, 428-428.	1.4	9
39	A Phase 3, Randomized, Adaptive Study of Defibrotide (DF) Vs Best Supportive Care (BSC) for the Prevention of Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Patients (pts) Undergoing Hematopoietic Cell Transplantation (HCT): Preliminary Results. <i>Blood</i> , 2021, 138, 749-749.	1.4	7
40	Veno-occlusive disease after high-dose busulfan+methylphalan in neuroblastoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 531-537.	2.4	17
41	Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. <i>Leukemia</i> , 2020, 34, 1202-1207.	7.2	61
42	Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2020, 111, 303-310.	1.6	7
43	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 415-422.	1.6	162
44	Partially CD3+-Depleted Unrelated and Haploidentical Donor Peripheral Stem Cell Transplantation Has Favorable Graft-versus-Host Disease and Survival Rates in Pediatric Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 493-501.	2.0	3
45	Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T cell therapy for B cell acute lymphoblastic leukemia in pediatric patients. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28092.	1.5	29
46	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. <i>Blood Advances</i> , 2020, 4, 5174-5183.	5.2	30
47	Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 5414-5424.	5.2	263
48	Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2741-2752.	1.6	36
49	Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic venous occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2020, 190, 583-587.	2.5	9
50	Thoracic duct lymphatic fluid harbors phenotypically naive T cells for use in adoptive T-cell therapy. <i>Cytotherapy</i> , 2020, 22, 529-535.	0.7	2
51	Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction. <i>Cancer Discovery</i> , 2020, 10, 552-567.	9.4	184
52	Dissecting the Tumor Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach. <i>Clinical Cancer Research</i> , 2020, 26, 3505-3513.	7.0	18
53	Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1239-1246.	2.0	56
54	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138

#	ARTICLE	IF	CITATIONS
55	Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. <i>Journal of Clinical Investigation</i> , 2020, 130, 5967-5975.	8.2	319
56	HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia. <i>Blood</i> , 2020, 136, 23-24.	1.4	4
57	Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β -Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells. <i>Blood</i> , 2020, 136, 3-4.	1.4	34
58	Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells. <i>Blood</i> , 2020, 136, 30-32.	1.4	4
59	CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2020, 38, 10511-10511.	1.6	15
60	Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response. <i>Human Gene Therapy</i> , 2019, 30, 168-178.	2.7	81
61	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1710-1718.	10.7	65
62	Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. , 2019, 7, 276.		101
63	Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 746.	7.4	220
64	Recent developments with defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 337-347.	0.8	4
65	CAR T cell viability release testing and clinical outcomes: is there a lower limit?. <i>Blood</i> , 2019, 134, 1873-1875.	1.4	24
66	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)â€”an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 1868-1880.	2.4	86
67	Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptorâ€”T Cells. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 285-295.	2.5	83
68	The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. <i>Blood Advances</i> , 2019, 3, 4034-4042.	5.2	63
69	CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. <i>Blood Advances</i> , 2019, 3, 3539-3549.	5.2	145
70	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. <i>Blood Advances</i> , 2019, 3, 3393-3405.	5.2	81
71	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 625-638.	2.0	1,741
72	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	85

#	ARTICLE	IF	CITATIONS
73	Na ⁺ ve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers. <i>Cancer Discovery</i> , 2019, 9, 492-499.	9.4	167
74	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. <i>Journal of Clinical Investigation</i> , 2019, 130, 673-685.	8.2	78
75	Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019. <i>Blood</i> , 2019, 134, 61-61.	1.4	3
76	Beginning the CAR T cell therapy revolution in the US and EU. <i>Current Research in Translational Medicine</i> , 2018, 66, 62-64.	1.8	24
77	The role of peritoneal drainage in veno-occlusive disease in pediatric patients post hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 938-941.	2.4	1
78	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 218-218.	27.6	93
79	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 439-448.	27.0	3,680
80	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2018, 131, 995-999.	1.4	170
81	Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27034.	1.5	26
82	High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. <i>Cancer Immunology Research</i> , 2018, 6, 36-46.	3.4	192
83	Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. <i>Cell Cycle</i> , 2018, 17, 468-478.	2.6	34
84	Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. , 2018, 6, 137.		182
85	Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2018, 24, 1504-1506.	30.7	393
86	Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. <i>Nature Medicine</i> , 2018, 24, 1499-1503.	30.7	459
87	Neurotoxicity after CTL019 in a pediatric and young adult cohort. <i>Annals of Neurology</i> , 2018, 84, 537-546.	5.3	82
88	Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 6175-6184.	7.0	170
89	False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy. <i>Blood</i> , 2018, 131, 2596-2598.	1.4	18
90	Final results from a defibrotide treatmentâ€‹IND study for patients with hepatic venoâ€‹occlusive disease/sinusoidal obstruction syndrome. <i>British Journal of Haematology</i> , 2018, 181, 816-827.	2.5	95

#	ARTICLE	IF	CITATIONS
91	CAR-T in the clinic: drive with care. <i>Gene Therapy</i> , 2018, 25, 157-161.	4.5	10
92	Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. <i>Blood</i> , 2018, 132, 1022-1026.	1.4	58
93	Reducing <i>Ex Vivo</i> Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. <i>Cancer Immunology Research</i> , 2018, 6, 1100-1109.	3.4	189
94	Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. <i>Journal of Hematology and Oncology</i> , 2018, 11, 35.	17.0	302
95	CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum. <i>Molecular and Cellular Biology</i> , 2018, 38, .	2.3	55
96	Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 959-971.	2.4	19
97	Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. <i>Cancer Discovery</i> , 2018, 8, 944-957.	9.4	313
98	Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 556-556.	1.4	106
99	High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada. <i>Blood</i> , 2018, 132, 1410-1410.	1.4	5
100	Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3044-3044.	1.6	3
101	Correlation of pre-CAR CD19 expression with responses and relapses after CAR T cell therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3051-3051.	1.6	3
102	Refining megatherapy, improving outcome in neuroblastoma. <i>Lancet Oncology</i> , The, 2017, 18, 423-424.	10.7	1
103	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 177-187.	1.4	138
104	Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. <i>Cytotherapy</i> , 2017, 19, 867-880.	0.7	116
105	Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. <i>Critical Care Medicine</i> , 2017, 45, e124-e131.	0.9	357
106	Defibrotide for Patients with Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 997-1004.	2.0	47
107	IFN γ directly inhibits murine B-cell precursor leukemia-initiating cell proliferation early in life. <i>European Journal of Immunology</i> , 2017, 47, 892-899.	2.9	13
108	Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. <i>Blood</i> , 2017, 130, 2317-2325.	1.4	273

#	ARTICLE	IF	CITATIONS
109	Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. <i>American Journal of Hematology</i> , 2017, 92, E11-E13.	4.1	78
110	Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL). <i>Blood</i> , 2017, 130, 653-653.	1.4	6
111	The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 103-103.	1.6	80
112	Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10507-10507.	1.6	16
113	Efficacy and safety of defibrotide (DF) to treat hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after primary chemotherapy (CT): A post hoc analysis of final data.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10513-10513.	1.6	1
114	Cardiac effects of chimeric antigen receptor (CAR) T-cell therapy in children.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10531-10531.	1.6	2
115	Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1^{c259}t in HLA-A2⁺ patients with synovial sarcoma (NCT01343043).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3000-3000.	1.6	20
116	Timing of initiation of defibrotide (DF) post-diagnosis of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after hematopoietic stem cell transplantation (HSCT): Final data from an expanded-access protocol.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7047-7047.	1.6	2
117	Effect of ONC201 and bortezomib on apoptosis in non-Hodgkin's lymphoma (NHL) xenografts.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19016-e19016.	1.6	1
118	Gene expression signatures of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with CLL and ALL.. <i>Journal of Clinical Oncology</i> , 2017, 35, 137-137.	1.6	1
119	Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10523-10523.	1.6	2
120	Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. <i>Journal of Immunological Methods</i> , 2016, 434, 1-8.	1.4	150
121	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2016, 6, 664-679.	9.4	811
122	CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia. <i>Current Treatment Options in Oncology</i> , 2016, 17, 28.	3.0	60
123	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. <i>Blood</i> , 2016, 127, 1656-1665.	1.4	255
124	Corrigendum to "Advances in T-cell therapy for ALL" [Best Pract Res Clin Haematol 27 (2014) 222-228]. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 133.	1.7	0
125	Cytokine Release Syndrome after Haploidentical Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1736-1737.	2.0	19
126	Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. <i>Blood</i> , 2016, 127, 17-28.	1.4	165

#	ARTICLE	IF	CITATIONS
127	T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. <i>Oncolmmunology</i> , 2016, 5, e1040216.	4.6	37
128	Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. <i>Science Translational Medicine</i> , 2016, 8, 320ra3.	12.4	224
129	Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis. <i>Blood</i> , 2016, 128, 2801-2801.	1.4	58
130	Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR. <i>Blood</i> , 2016, 128, 281-281.	1.4	16
131	Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function. <i>Blood</i> , 2016, 128, 654-654.	1.4	23
132	Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation: Exploratory Age-Group Analysis from an Expanded Access Study. <i>Blood</i> , 2016, 128, 66-66.	1.4	3
133	Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children's Oncology Group (COG) study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10528-10528.	1.6	3
134	Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3007-3007.	1.6	17
135	Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3009-3009.	1.6	22
136	Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3011-3011.	1.6	98
137	Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7002-7002.	1.6	32
138	A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA3-LBA3.	1.6	17
139	Autologous genetically engineered NY-ESO-1^{c259}T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3101-TPS3101.	1.6	3
140	A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA3-LBA3.	1.6	31
141	IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. <i>Blood</i> , 2015, 125, 3501-3508.	1.4	177
142	Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. <i>Blood</i> , 2015, 126, 629-639.	1.4	110
143	CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 4017-4023.	1.4	598
144	Chimeric Antigen Receptor and TCR-Modified T Cells Enter Main Street and Wall Street. <i>Journal of Immunology</i> , 2015, 195, 755-761.	0.8	147

#	ARTICLE	IF	CITATIONS
145	Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 1759-1767.	1.4	189
146	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. <i>Science Translational Medicine</i> , 2015, 7, 303ra139.	12.4	1,402
147	Convergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy. <i>Cancer Discovery</i> , 2015, 5, 1282-1295.	9.4	997
148	TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 67-73.	2.0	62
149	Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 402-411.	2.0	8
150	Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 1334-1334.	1.4	5
151	Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies. <i>Blood</i> , 2015, 126, 2523-2523.	1.4	7
152	Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL. <i>Blood</i> , 2015, 126, 3769-3769.	1.4	40
153	Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL. <i>Blood</i> , 2015, 126, 683-683.	1.4	22
154	Defibrotide for the Treatment of Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial. <i>Blood</i> , 2015, 126, 737-737.	1.4	1
155	Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3102-TPS3102.	1.6	6
156	Resource utilization (RU) and toxicities after carboplatin/etoposide/melphalan (CEM) and busulfan/melphalan (BuMel) for autologous stem cell rescue (ASCR) in high-risk neuroblastoma (HRNB).. <i>Journal of Clinical Oncology</i> , 2015, 33, e21009-e21009.	1.6	0
157	Association of higher lung dose received during total body irradiation for allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia with inferior progression-free and overall survival: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10030-10030.	1.6	3
158	Defibrotide for the Treatment of Patients with Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ Dysfunction Following Chemotherapy: Results from an Ongoing Expanded Access Program. <i>Blood</i> , 2015, 126, 3121-3121.	1.4	0
159	Chimeric antigen receptor T-cell therapy for ALL. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 559-564.	2.5	58
160	Advances in T-cell therapy for ALL. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 222-228.	1.7	15
161	Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 119-122.	2.0	624
162	Roadblocks to success for RNA CARs in solid tumors. <i>Oncolmmunology</i> , 2014, 3, e962974.	4.6	13

#	ARTICLE	IF	CITATIONS
163	Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood</i> , 2014, 124, 188-195.	1.4	2,080
164	Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. <i>Cytotherapy</i> , 2014, 16, 619-630.	0.7	90
165	Nature of Tumor Control by Permanently and Transiently Modified GD2 Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma. <i>Cancer Immunology Research</i> , 2014, 2, 1059-1070.	3.4	62
166	Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 1507-1517.	27.0	4,444
167	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. <i>Blood</i> , 2014, 124, 1372-1377.	1.4	178
168	Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL. <i>Blood</i> , 2014, 124, 1982-1982.	1.4	38
169	Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL. <i>Blood</i> , 2014, 124, 1983-1983.	1.4	6
170	Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells. <i>Blood</i> , 2014, 124, 2296-2296.	1.4	37
171	T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL. <i>Blood</i> , 2014, 124, 380-380.	1.4	14
172	Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies. <i>Blood</i> , 2014, 124, 966-966.	1.4	4
173	Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy. <i>Blood</i> , 2014, 124, 1110-1110.	1.4	4
174	Defibrotide for the Treatment of Severe Hepatic Venous Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. <i>Blood</i> , 2014, 124, 2469-2469.	1.4	0
175	Updated Results from a Large, Ongoing, Treatment IND Study Using Defibrotide for Patients with Hepatic Venous Occlusive Disease. <i>Blood</i> , 2014, 124, 2470-2470.	1.4	0
176	Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1044-1047.	1.5	14
177	Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2013, 368, 1509-1518.	27.0	3,021
178	Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models. <i>Blood</i> , 2013, 122, 143-143.	1.4	9
179	Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19. <i>Blood</i> , 2013, 122, 163-163.	1.4	22
180	In Vivo Efficacy of PI3K Pathway Signaling Inhibition for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 2672-2672.	1.4	5

#	ARTICLE	IF	CITATIONS
181	Targeting mTOR Signaling Leads To Complete and Durable Responses In Children With Multi-Lineage Autoimmune Cytopenias, Including ALPS, SLE, Evans and CVID. <i>Blood</i> , 2013, 122, 330-330.	1.4	2
182	Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL. <i>Blood</i> , 2013, 122, 4162-4162.	1.4	14
183	T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL. <i>Blood</i> , 2013, 122, 67-67.	1.4	17
184	Results Of The Large Prospective Study On The Use Of Defibrotide (DF) In The Treatment Of Hepatic Venous Occlusive Disease (VOD) In Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome - Updated Results Of a Treatment IND (T-IND) Expanded Access Protocol. <i>Blood</i> , 2013, 122, 700-700.	1.4	8
185	Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL. <i>Blood</i> , 2013, 122, 873-873.	1.4	13
186	Adoptive Transfer of Autologous T Cells Improves T-cell Repertoire Diversity and Long-term B-cell Function in Pediatric Patients with Neuroblastoma. <i>Clinical Cancer Research</i> , 2012, 18, 6732-6741.	7.0	39
187	Neuroblastoma: Issues in Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S92-S100.	2.0	20
188	Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies. <i>Paediatric Drugs</i> , 2012, 14, 299-316.	3.1	31
189	The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse. <i>Blood</i> , 2012, 120, 470-470.	1.4	4
190	Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL. <i>Blood</i> , 2012, 120, 717-717.	1.4	10
191	Results of a Large Prospective Study On the Use of Defibrotide (DF) in the Treatment of Hepatic Venous Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome - Updated Results of a Treatment IND (T-IND) Expanded Access Protocol. <i>Blood</i> , 2012, 120, 738-738.	1.4	1
192	Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. <i>Blood</i> , 2012, 120, 739-739.	1.4	19
193	In vivo monitoring of JAK/STAT and PI3K/mTOR signal transduction inhibition in pediatric CRLF2-rearranged acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2012, 30, 9506-9506.	1.6	0
194	Sustained Functional T Cell Persistence and B Cell Aplasia Following CD19-Targeting Adoptive T Cell Immunotherapy for Relapsed, Refractory CD19+ Malignancy. <i>Blood</i> , 2012, 120, 756-756.	1.4	1
195	Evaluation of Defibrotide (DF) in the Treatment of Hepatic Venous Occlusive Disease (VOD) in Non-Stem Cell Transplant (non-SCT) Chemotherapy Patients (pts): Results From the Treatment IND (T-IND) Expanded Access Protocol and the Compassionate Use Program (CUP).. <i>Blood</i> , 2012, 120, 3041-3041.	1.4	0
196	CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).. <i>Blood</i> , 2012, 120, 2604-2604.	1.4	6
197	Immune Profiling Suggests an IGH Signaling-Dependent Subtype of Aggressive B-ALL. <i>Blood</i> , 2012, 120, 1428-1428.	1.4	0
198	A Novel Model of Immune-Mediated Disease Equilibrium in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 3540-3540.	1.4	0

#	ARTICLE	IF	CITATIONS
199	T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. <i>Science Translational Medicine</i> , 2011, 3, 95ra73.	12.4	2,006
200	Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. <i>Blood</i> , 2011, 118, e112-e117.	1.4	49
201	Defibrotide (DF) in the Treatment of Hepatic Venno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol. <i>Blood</i> , 2011, 118, 487-487.	1.4	3
202	A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431. <i>Blood</i> , 2011, 118, 837-837.	1.4	1
203	Targeting mTOR and JAK2 in Xenograft Models of CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2011, 118, 249-249.	1.4	1
204	Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience. <i>Blood</i> , 2011, 118, 3074-3074.	1.4	0
205	Adoptive Cellular Therapy. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 149-172.	1.1	22
206	Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of Leukemia. <i>Blood</i> , 2010, 116, 2140-2140.	1.4	1
207	Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Venno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).. <i>Blood</i> , 2010, 116, 3481-3481.	1.4	5
208	Defibrotide (DF) In the Treatment of Severe Hepatic Venno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol. <i>Blood</i> , 2010, 116, 906-906.	1.4	3
209	Targeting mTOR Signaling Is An Effective Treatment Strategy for IKAROS and JAK Kinase Mutated Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 3251-3251.	1.4	0
210	Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. <i>Molecular Therapy</i> , 2009, 17, 1453-1464.	8.2	988
211	Immunotherapy for Pediatric Cancer. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 33-43.	2.0	8
212	Signal Transduction Inhibitors in Lymphoproliferative Diseases (LPD).. <i>Blood</i> , 2008, 112, sci-10-sci-10.	1.4	0
213	Targeting HMG-CoA Reductase in Acute Lymphoblastic Leukemia (ALL): Statins Inhibit Proliferation and Induce Apoptosis in ALL Cells. <i>Blood</i> , 2008, 112, 2927-2927.	1.4	4
214	Is G-CSF-mobilized peripheral stem cell harvest harmful?â€”Response. <i>Pediatric Blood and Cancer</i> , 2007, 48, 597-597.	1.5	0
215	A Phase I Trial of Sirolimus (Rapamycin) in Pediatric Patients with Relapsed/Refractory Leukemia.. <i>Blood</i> , 2007, 110, 2834-2834.	1.4	7
216	CpG Oligonucleotides Induce Anti-Leukemia Activity in a Syngeneic Murine Model of Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2007, 110, 2830-2830.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Stem cells support multiple cycles of high-dose induction therapy: Lots from tots. <i>Pediatric Blood and Cancer</i> , 2006, 46, 715-716.	1.5	0
218	Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: Saving for a rainy day. <i>Pediatric Blood and Cancer</i> , 2006, 46, 719-722.	1.5	19
219	Use of G-CSF in Matched Sibling Donor Pediatric Allogeneic Transplantation: A Consensus Statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMT) Executive Committee. <i>Pediatric Blood and Cancer</i> , 2006, 46, 414-421.	1.5	46
220	In Vivo Control of Acute Lymphoblastic Leukemia by Immunostimulatory CpG Oligonucleotides.. <i>Blood</i> , 2006, 108, 1868-1868.	1.4	15
221	Chimeric Immunoreceptor (T-Body) Targeting of Acute B-Cell Lymphoblastic Leukemia (B-ALL) through Lentivirus Engineering of Primary Human T Cells.. <i>Blood</i> , 2006, 108, 3267-3267.	1.4	0
222	A Prospective Study of G-CSF Primed Bone Marrow from Pediatric Donors as a Stem Cell Source for Allogeneic Bone Marrow Transplant: A Pediatric Blood and Marrow Transplant Consortium (PBMT) Study.. <i>Blood</i> , 2005, 106, 1964-1964.	1.4	3
223	Murine Ultrasonography Confirms That Rapamycin Is Effective Against Autoimmune Lymphoproliferative Syndrome (ALPS).. <i>Blood</i> , 2005, 106, 2386-2386.	1.4	1
224	Unrelated Donor (URD) or Partially Matched Related Donor (PMRD) Peripheral Stem Cell Transplant (PSCT) with CD34+ Selection and CD3+ Addback for Pediatric Patients with Leukemias.. <i>Blood</i> , 2004, 104, 2159-2159.	1.4	0
225	IL-7 and Thymic Stromal Lymphopoietin (TSLP) Stimulate Proliferation of All Cells and Reverse mTOR Inhibitor-Induced Growth Inhibition, Suggesting a Role for IL-7R α Signaling in All.. <i>Blood</i> , 2004, 104, 1893-1893.	1.4	0
226	Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. <i>Medical and Pediatric Oncology</i> , 2000, 35, 673-676.	1.0	19
227	CD34 selection as a stem cell purging strategy for neuroblastoma: Preclinical and clinical studies. <i>Medical and Pediatric Oncology</i> , 2000, 35, 677-682.	1.0	38
228	Rapid-sequence tandem transplant for children with high-risk neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2000, 35, 696-700.	1.0	37
229	Low rate of subsequent malignant neoplasms following CAR T-cell therapy. <i>Blood Advances</i> , 0, , .	5.2	8